SVAIX | VIVIX | SVAIX / VIVIX | |
Total Expense Ratio | 0.81 | 0.04 | 2,025% |
Annual Report Gross Expense Ratio | 0.93 | 0.04 | 2,325% |
Fund Existence | 21 years | 27 years | - |
Gain YTD | 13.103 | 9.748 | 134% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000000 | 5000000 | 20% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 8.67B | 208B | 4% |
Annual Yield % from dividends | 3.20 | 2.09 | 153% |
Returns for 1 year | 5.92 | 4.64 | 127% |
Returns for 3 years | 30.98 | 42.98 | 72% |
Returns for 5 years | 67.84 | 71.78 | 95% |
Returns for 10 years | 47.30 | 129.40 | 37% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
SIGWX | 7.37 | 0.05 | +0.68% |
Touchstone Small Company Y | |||
JAGLX | 75.17 | 0.46 | +0.62% |
Janus Henderson Global Life Sciences T | |||
GMVRX | 16.40 | 0.04 | +0.24% |
Goldman Sachs Small/Mid Cap Equity R | |||
CLBCX | 38.97 | 0.03 | +0.08% |
American Funds American Balanced 529C | |||
MIQBX | 12.30 | 0.01 | +0.08% |
Morgan Stanley Inst International Eq A |